GSK

GSK First Quarter 2025 Performance Report

• GSK reported total Q1 2025 sales of £7.5 billion, representing a 2% increase at actual exchange rates (AER) and 4% at constant exchange rates (CER).
• Specialty Medicines served as the primary growth driver, with sales rising 17% to £2.9 billion.
• Oncology and Respiratory, Immunology, and Inflammation segments saw significant growth, with sales increasing by 53% to £0.4 billion and 28% to £0.8 billion, respectively.